Yahoo Finance

• Total Revenue: $9.6 million in Q4 2024, up 10% from $8.7 million in Q4 2023.

• Global Net Recurring Revenue: $5.8 million in Q4 2024, compared to $5.6 million in Q4 2023.

• Gross Domestic Revenue Billings: $4.9 million in Q4 2024, showing sequential increases from previous quarters.

• Equipment Revenue: $3.8 million in Q4 2024, up from $3.1 million in Q4 2023.

• Gross Profit: Increased to $5.8 million in Q4 2024 from $4.8 million in Q4 2023.

• Gross Margin: Improved to 60.1% in Q4 2024 from 55.3% in Q4 2023.

• Operating Expenses: $10 million in Q4 2024, compared to $8.2 million in Q4 2023.

• Normalized Operating Expenses: $6.1 million in Q4 2024, slightly up from $6 million in Q4 2023.

• Cash Equivalents and Restricted Cash: $8.6 million as of December 30, 2024.

• Installed Base of Therapy X Devices: 144 devices in the U.S. at the end of Q4 2024, up from 92 at the end of 2023.

• International Sales: $4.1 million in Q4 2024, up 27% from Q3 2024 and 41% from Q4 2023.

• Common Shares Outstanding: 4,171,161 as of December 30, 2024.

• Warning! GuruFocus has detected 5 Warning Signs with SSKN.

Release Date: March 27, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Strata Skin Sciences Inc (NASDAQ:SSKN) reported a strong fourth quarter with a significant improvement in average net revenue per device, up 11% over the previous quarter and 6% over the prior year.

• The company's gross margin improved to 60%, showing a 480-basis point improvement over the prior year Q4.

• International sales were particularly strong, with a 27% increase over the third quarter and a 41% increase over Q4 2023, marking the highest level of international sales to date.

• The company successfully secured pre-authorization for over 3,700 acne patients in partner clinics, indicating strong adoption of their insurance-reimbursed treatments.

• Strata Skin Sciences Inc (NASDAQ:SSKN) achieved a third consecutive quarter of sequential increase in gross domestic revenue billings, highlighting the effectiveness of their strategic efforts.

Negative Points

• The US extract install base declined from 923 to 864, indicating a reduction in the number of devices in operation.

• Total operating expenses for the fourth quarter of 2024 increased to $10 million from $8.2 million in the year-ago period.

• The company experienced a sequential decline of 22% between Q4 2023 and Q1 2024, reflecting a strong seasonal effect.

• Global net recurring revenue for the fourth quarter of 2024 was only slightly up at $5.8 million compared to $5.6 million in the fourth quarter of 2023.

• The company faces challenges in the Chinese and Korean markets due to economic changes and competitor bankruptcies, affecting local market distributors.